It plays a pivotal role in energy balance and postprandial metabolism by enhancing glucose-dependent insulin secretion, suppressing glucagon release, delaying gastric emptying, and promoting satiety through central mechanisms [8, 9]
Type 2 diabetes: insulin degludec/liraglutide (Xultophy) Evidence summary ESNM60
10.1177/1087057113493006 J
Epidemiology shows that approximately 40% of diabetic patients develop DKD, but this figure changes according to the diagnostic guidelines for DKD [6, 7].DKD has a high disease burden worldwide and significantly increases the risk of renal failure and cardiovascular events [8]
Weight loss with GLP-1 medications typically follows the pattern seen in clinical trials, with more rapid loss in early months that gradually slows
Before your first session, ask how they typically structure treatment, what kinds of homework they assign, and how progress is measured